{"disease":{"id":"body","name":"body"},"drugs":{"marketed":[{"drug_id":"avacopan","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"AVACOPAN","company_name":"Chemocentryx","drug_phase":"marketed","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist [EPC]","quality_score":62,"revenue":"400","mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response."},{"drug_id":"gallium-68ga-edotreotide","indication_name":"Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ga 68 Dotatate","generic_name":"gallium (68Ga) edotreotide","company_name":"Uihc Pet Imaging","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"","quality_score":32,"revenue":"305","mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ccx168","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"CCX168","company_name":"Chemocentryx","drug_phase":"discontinued","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist","quality_score":null,"revenue":null,"mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels."},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"zonegran","indication_name":"Diffuse Lewy body disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zonegran","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02285868","title":"ATI Evidence-based Guide Investigating Clinical Services","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000000,"lead_sponsor_name":"ATI Holdings, LLC","has_results":false},{"nct_id":"NCT03085875","title":"POWERMOM, A Healthy Pregnancy Research Community","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT07135115","title":"Targeting Lifestyle to Improve Colorectal Cancer Screening","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT05765162","title":"Safe Brain Initiative, Operationalizing Precision Anaesthesia","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03400761","title":"Does Body Composition Predict Running Time?","phase":"","overall_status":"COMPLETED","enrollment_count":13000,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT07430618","title":"Real-World Two-Year Weight Loss Outcomes With Breath Biofeedback","phase":"","overall_status":"COMPLETED","enrollment_count":11524,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04827615","title":"Evaluation of the Ambuja Cement Foundation Noncommunicable Disease Program in Bathinda District of Punjab, India","phase":"NA","overall_status":"COMPLETED","enrollment_count":11322,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT05710913","title":"Development of Machine Learning Models for the Prediction of BMI and Complications After Bariatric Surgery (CABS-Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Dr. Med Anas Taha","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT05084950","title":"Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Centre Scientifique de Monaco","has_results":false},{"nct_id":"NCT05493449","title":"Impact of School Milk Program on Nutritional Status of Primary School Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":7799,"lead_sponsor_name":"University of Veterinary and Animal Sciences, Lahore - Pakistan","has_results":false},{"nct_id":"NCT00341276","title":"Esophageal Cancer Genetics Studies","phase":"","overall_status":"COMPLETED","enrollment_count":7705,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07161167","title":"Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6743,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03408158","title":"HPA Antibodies and the Distribution of Antigen and Antibodies","phase":"NA","overall_status":"COMPLETED","enrollment_count":6170,"lead_sponsor_name":"Guangzhou First People's Hospital","has_results":false},{"nct_id":"NCT06021925","title":"Obstetrical History and Anti-HLA Antibodies Level","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04143074","title":"Community Based Obesity Prevention and Treatment Programme \"6-10-14 for Health\"","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Michał Brzeziński","has_results":false},{"nct_id":"NCT04776460","title":"The Distribution of Body Constitutions Among Hong Kong Elderly Population: A Cross-sectional Study","phase":"","overall_status":"COMPLETED","enrollment_count":5300,"lead_sponsor_name":"Hong Kong Baptist University","has_results":false},{"nct_id":"NCT06385457","title":"The Effects of Mindhelper.dk: a Self-guided Digital Mental Health Promotion Service Targeting Young People","phase":"NA","overall_status":"RECRUITING","enrollment_count":4910,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT05248763","title":"Taiwan Cancer Moonshot Project","phase":"","overall_status":"RECRUITING","enrollment_count":4190,"lead_sponsor_name":"Academia Sinica, Taiwan","has_results":false},{"nct_id":"NCT05834894","title":"Does Muscle Mass At Intensive Care Unit Admission Determine Mortality: the Memo Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University Hospital, Geneva","has_results":false},{"nct_id":"NCT06584305","title":"AI Screening for BDD in Aesthetic Surgery: Enhancing Safety and Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":3722,"lead_sponsor_name":"Bukret Plastic Surgery","has_results":false},{"nct_id":"NCT03396029","title":"Tailored Written Lifestyle Feedback in Colorectal Cancer Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":3642,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT05669053","title":"The Impact of Playing Super U on Pre-adolescents' Body Image","phase":"NA","overall_status":"COMPLETED","enrollment_count":2941,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT05219097","title":"The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis","phase":"","overall_status":"COMPLETED","enrollment_count":2663,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT04317755","title":"Evaluation of the Impact of a Comic-based Programme to Promote Body Confidence Among Adolescents in India","phase":"NA","overall_status":"COMPLETED","enrollment_count":2631,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT07309484","title":"Lifestyle and Its Association With Maintaining Health","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"University of Zadar","has_results":false},{"nct_id":"NCT04429581","title":"Differences in Fat Mass Estimation Formulas in Physically Active Adult Population and Relation With Skinfold Sums.","phase":"","overall_status":"COMPLETED","enrollment_count":2458,"lead_sponsor_name":"Universidad Católica San Antonio de Murcia","has_results":false},{"nct_id":"NCT04591470","title":"Influence of Inguinal Hernia Repair on Sperm Autoimmunity","phase":"","overall_status":"COMPLETED","enrollment_count":2415,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT03397940","title":"Role of Structured Days on Weight Gain","phase":"","overall_status":"COMPLETED","enrollment_count":2279,"lead_sponsor_name":"University of South Carolina","has_results":false},{"nct_id":"NCT06308744","title":"A Large Multi-site Study on Self-administered Mindfulness","phase":"NA","overall_status":"COMPLETED","enrollment_count":2239,"lead_sponsor_name":"Swansea University","has_results":false},{"nct_id":"NCT04931589","title":"A Multicentre Study of Intraoperative Body Temperature Changes in Patients Undergoing Thoracoscopic Radical Surgery for Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2156,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05545371","title":"Prevention of Rabies With Four Doses of Rabies Vaccine","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2100,"lead_sponsor_name":"Changchun Zhuoyi Biological Co., Ltd","has_results":false},{"nct_id":"NCT04766203","title":"Relative Energy Deficiency in Sport Multicenter Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Trent Stellingwerff","has_results":false},{"nct_id":"NCT05383807","title":"Evaluating a Social Media-Based Intervention to Reduce Body Dissatisfaction Among Young Indonesian Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05215132","title":"Investigational MRI Clinical Software and Hardware","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06811519","title":"AI-based Prediction of Cardiac Function Using Echocardiography and Body Composition Data (ECHO-FIT Study)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03920098","title":"Chilean Maternal & Infant Cohort Study II (CHiMINCs-II)","phase":"","overall_status":"UNKNOWN","enrollment_count":1927,"lead_sponsor_name":"Instituto de Nutrición y Tecnología de los Alimentos","has_results":false},{"nct_id":"NCT04665557","title":"Evaluating Dove Confident Me Single Session in Indonesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":1926,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT05943483","title":"To Establish the Traditional Chinese Medicine Based Intelligent Personal Health Care System","phase":"","overall_status":"COMPLETED","enrollment_count":1918,"lead_sponsor_name":"Sheng-Teng Huang","has_results":false},{"nct_id":"NCT05023213","title":"Evaluating an Social Media Intervention to Reduce Body Dissatisfaction Among Young Indonesian Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":1857,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT07113678","title":"The Impact of a Podcast-based Body Image Intervention Among Millennial Women","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT05549908","title":"Vaccine Prevention of Rabies Adopts 4-shot Immunization Method","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Changchun Zhuoyi Biological Co., Ltd","has_results":false},{"nct_id":"NCT04825184","title":"The Impact of an Artificial Intelligence Chatbot on Brazilian Adolescents' Body Image","phase":"NA","overall_status":"COMPLETED","enrollment_count":1715,"lead_sponsor_name":"University of the West of England","has_results":false},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}